Feb 3 |
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain
|
Feb 1 |
Atara spikes on peer-reviewed Phase 3 data for lead asset
|
Jan 31 |
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
|
Jan 11 |
Seth Klarman's Exit from Atara Biotherapeutics Inc
|
Jan 11 |
Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
|
Jan 8 |
Atara to conduct $15M registered direct offering
|
Jan 8 |
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
|
Jan 8 |
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 4 |
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 20 |
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
|